A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P‐glycoprotein activity in vitro

Abstract

P‐glycoprotein (P‐gp), a multidrug resistance (MDR) protein encoded by the MDR1 gene in humans, is responsible for the efflux of structurally diverse drugs. Previous studies in our laboratory have shown that excipients such as poly(ethylene)glycol (PEG)‐300, Cremophor EL, and Tween 80 inhibit P‐gp activity in Caco‐2 cell monolayers. The objective of this study was to determine the effects of these excipients in an MDR1‐ transfected Madin Darby Canine Kidney (MDR1‐MDCK) cell line and to compare the results with those obtained from Caco‐2 cells. The results presented herein show that PEG‐300 (20%, v/v) causes almost complete inhibition of P‐gp activity in both Caco‐2 and MDR1‐MDCK cell monolayers, whereas Cremophor EL (0.1%, w/v) and Tween 80 (0.05%, w/v) only partially inhibit P‐gp activity in Caco‐2 cells. Cremophor EL (0.1%, w/v) and Tween 80 (0.05%, w/v) were inactive as P‐gp inhibitors in MDR1‐MDCK cell monolayers. This inability of Tween 80 and Cremphor EL to inhibit P‐gp activity in MDR1‐MDCK cells may be related to differences in the interactions of the surfactants with these different cell membranes. PEG‐induced changes in P‐gp activity are probably related to changes in the fluidity of the polar head group regions of cell membranes. © 2002 Wiley‐Liss Inc. and the American Pharmaceutical Association J Pharm Sci 91:1991–2002, 2002